Influence of age as a continuous variable on the prognosis of patients with pT1-2N1 breast cancer
Xu-Ran Zhao,
Yu Tang,
Hong-Fen Wu,
Qi-Shuai Guo,
Yu-Jing Zhang,
Mei Shi,
Jing Cheng,
Hong-Mei Wang,
Min Liu,
Chang-Ying Ma,
Ge Wen,
Xiao-hu Wang,
Hui Fang,
Hao Jing,
Yong-Wen Song,
Jing Jin,
Yue-Ping Liu,
Bo Chen,
Shu-Nan Qi,
Ning Li,
Yuan Tang,
Ning-Ning Lu,
Na Zhang,
Ye-Xiong Li,
Shu-Lian Wang
Affiliations
Xu-Ran Zhao
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
Yu Tang
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
Hong-Fen Wu
Department of Radiation Oncology, Jilin Cancer Hospital, Changchun, China
Qi-Shuai Guo
Department of Radiation Oncology, Affiliated Cancer Hospital of Chongqing University, Chongqing, China
Yu-Jing Zhang
Department of Radiation Oncology, Sun Yat-sen University Affiliated Tumor Hospital, Guangzhou, China
Mei Shi
Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, China
Jing Cheng
Department of Breast Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Hong-Mei Wang
Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Min Liu
Department of Radiation Oncology, First Hospital of Jilin University, Changchun, China
Chang-Ying Ma
Department of Radiation Oncology, First Hospital of Qiqihaer, Qiqihaer, China
Ge Wen
Department of Radiation Oncology, Sun Yat-sen University Affiliated Tumor Hospital, Guangzhou, China; Department of Radiation Oncology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Xiao-hu Wang
Department of Radiation Oncology, Gansu Cancer Hospital, Lanzhou, China
Hui Fang
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
Hao Jing
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
Yong-Wen Song
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
Jing Jin
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
Yue-Ping Liu
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
Bo Chen
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
Shu-Nan Qi
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
Ning Li
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
Yuan Tang
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
Ning-Ning Lu
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
Na Zhang
Department of Radiation Oncology, Liaoning Cancer Hospital, Shenyang, China; Corresponding author.
Ye-Xiong Li
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China; Corresponding author.
Shu-Lian Wang
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China; Corresponding author.
Purpose: To assess the influence of age as a continuous variable on the prognosis of pT1-2N1 breast cancer and examine its decision-making value for postmastectomy radiotherapy (PMRT). Methods: We retrospectively evaluated 5438 patients with pT1-2N1 breast cancer after mastectomy in 11 hospitals. A multivariable Cox proportional hazards regression model with penalized splines was used to examine the relationship between age and oncologic outcomes. Results: The median follow-up was 67.0 months. After adjustments for confounding characteristics, nonsignificant downward trend in locoregional recurrence (LRR) risk was observed with increasing age (P-non-linear association = 0.640; P-linear association = 0.078). A significant non-linear association was found between age and disease-free survival (DFS) and overall survival (OS) (P-non-linear association 0.05, respectively). The DFS and OS exhibited U-shaped relationships, with the hazard ratios (HRs), reaching a nadir at 50 years old. A decreased risk of LRR with PMRT vs. no PMRT (HR = 0.304, 95% CI: 0.204–0.454) was maintained in all ages. The HR of PMRT vs. no PMRT for DFS and OS gradually increased with age. In patients ≤50 years old, PMRT was independently associated with favorable LRR, DFS, and OS, all P 50 years old, PMRT was independently associated with reduced LRR (P = 0.004), but had no effect on DFS or OS. Conclusions: Age was an independent prognostic factor for pT1-2N1 breast cancer; PMRT provided survival benefits for patients ≤50 years old, but not for patients >50 years old.